L. Minion

Anti-angiogenic agents in ovarian cancer: past, present, and future.

B. Monk, R. Coleman, L. Minion, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Incidence and management of edema associated with trebananib (AMG 386).

B. Monk, B. Karlan, I. Vergote, 2013, Gynecologic oncology.

Safety and efficacy of salvage nano-particle albumin bound paclitaxel in recurrent cervical cancer: a feasibility study

B. Monk, D. Chase, J. Farley, 2015, Gynecologic Oncology Research and Practice.

Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition.

K. Tewari, Krishnansu S Tewari, Lindsey E Minion, 2018, Gynecologic oncology.

The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer

K. Tewari, L. Minion, 2017, Expert review of anticancer therapy.

Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2.

B. Monk, E. Chao, D. Chase, 2014, Gynecologic oncology.

A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer.

Jiaru Bai, B. Monk, J. Chan, 2015, Gynecologic oncology.

Endpoints in clinical trials: What do patients consider important? A survey of the Ovarian Cancer National Alliance.

R. Coleman, T. Herzog, R. Alvarez, 2013, Gynecologic oncology.